Immunovant (IMVT) PT Raised to $57 at Stifel

August 6, 2026 9:50 AM

Stifel analyst Alex Thompson raised the price target on Immunovant (NASDAQ: IMVT) to $57.00 (from $49.00) while maintaining a Buy rating.

No results found